A 10-Minute Gene Therapy That Protects You For 10+ Years | Dr Noah Davidsohn

Join us as Dr. Noah Davidsohn, Co-Founder and Chief Scientific Officer of Rejuvenate Bio, reveals how systemic multi-gene therapy and in vivo partial cellular reprogramming can reverse age-related chronic diseases and double remaining lifespan. Discover the breakthrough science of AAV vector delivery, FGF21 and sTGFβR2 synergy, and companion animal clinical translation. 🩸 Track Your Key Longevity & Cardiovascular Biomarkers with SiPhox Health: Get comprehensive at-home blood testing for ApoB, inflammation (hs-CRP), metabolic health, and hormone levels: 👉https://siphoxinc.pxf.io/6y1NaQ (Use code MODERN for 20% discount) If you would like to support our channel please consider joining our Patreon:   / modernhealthspan   What if a single gene therapy injection could simultaneously treat heart failure, kidney disease, and diabetes? In this episode, we sit down with Dr. Noah Davidsohn, CSO and Co-Founder of Rejuvenate Bio, spun out of George Church’s lab at Harvard Medical School. Dr. Davidsohn breaks down their landmark 2024 study in Cellular Reprogramming, which demonstrated a 109% increase in the remaining lifespan of extremely aged (124-week-old) wild-type mice using systemic AAV9 delivery of Yamanaka factors (OSK). He explains the mechanics of intermittent doxycycline pulsing to avoid tumor risks, the power of multi-gene master regulators like FGF21 and sTGFβR2 in RJB-01, and how treating companion dogs with Mitral Valve Disease serves as the ultimate translational bridge to human clinical trials. 📚 Chapters 00:00 Canine Mitral Valve Disease Trial Updates (Tufts Pilot) 03:26 Translating Dog Longevity Data to Humans 06:18 FGF21: Cardiac Calcium Signaling & Cellular Protection 09:23 Targeting Root Drivers of Aging vs. Polypharmacy 12:04 Partial Cellular Reprogramming & Yamanaka Factors (OSK) 13:45 109% Lifespan Doubling in 124-Week-Old Elderly Mice 17:14 Intermittent Doxycycline Pulsing to Prevent Teratomas 22:03 Frailty Index Reversal & Quality of Life in Aged Mice 25:48 Epigenetic Clock Reversal in Heart, Liver & Muscle 27:44 Comparing OSK Reprogramming Across Global Labs (Altos, Life Bio) 32:02 In Vivo vs. In Vitro Cellular Reprogramming Dynamics 36:02 Non-Integrating AAV Episomal Safety 38:49 Dropping Gene Therapy Costs to $2,000 Per Dose 40:24 Immune Tolerance: Mice vs Dogs vs Humans 41:19 Human Clinical Trial Timelines (Next 1–2 Years) 45:00 Cell-Specific Rejuvenation vs Single Magic Bullet 48:25 Future Regulatory Paths: ARPA-H & Longevity Biomarkers 🔬 Scientific Citations & References Mentioned 1. Davidsohn, N., et al. (2019). A single systemic gene therapy delivery of FGF21 and sTGFβR2 simultaneously treats multiple age-related diseases in mice. Proceedings of the National Academy of Sciences (PNAS). 2. Macip, S., et al. (2024). Systemic AAV9-mediated delivery of Yamanaka factors extends remaining lifespan in elderly wild-type mice. Cellular Reprogramming. 3. Rejuvenate Bio Preclinical Pipeline Data on RJB-0402 (Desmoplakin Arrhythmogenic Cardiomyopathy) & Companion Animal MMVD Trials. 🌐 Links in this video: Rejuvenate Bio Website: https://www.rejuvenatebio.com WeFund for Rejuvenate Bio: https://wefunder.com/rejuvenatebio Medical Disclaimer: The content of this video is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any changes to your health regimen, supplement stack, or undertaking medical therapies. #Longevity #GeneTherapy #CellularReprogramming #AntiAging #RejuvenateBio #Healthspan #GeorgeChurch #Biotech #HealthyAging #ModernHealthspan